Antonio Mirijello

Dr. Antonio Mirijello

Casa Sollievo della Sofferenza Hospital IRCCS
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in JACC
Verified
Journal Article
Open access
GRGregory A. Roth
Gregory A. Roth
GMGeorge A. Mensah
George A. Mensah
CJCatherine O. Johnson
Catherine O. Johnson
GAGiovanni Addolorato
Giovanni Addolorato
EAEnrico Ammirati
Enrico Ammirati
CMChristopher J.L. Murray
Christopher J.L. Murray
Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortality and a major contributor to disability. This paper reviews the magnitude of total CVD burden, including 13 underlying causes of cardiovascular death and 9 related risk factors, using estimates from the Global Burden of Disease (GBD) Study 2019. GBD, an ongoing multinational collaboration to provide comparable and consistent estimates of population health over time, used all available population-level data sources on incidence, prevalence, case fatality, mortality, and health risks to produce estimates for 204 countries and territories from 1990 to 2019.

1 December 2007 in The Lancet
Verified
Journal Article
Closed access
GAGiovanni Addolorato
Giovanni Addolorato
LLLorenzo Leggio
Lorenzo Leggio
AFAnna Ferrulli
Anna Ferrulli
SCSilvia Cardone
Silvia Cardone
LVLuisa Vonghia
Luisa Vonghia
GGGiovanni Gasbarrini
Giovanni Gasbarrini

11 April 2013 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
GAGiovanni Addolorato
Giovanni Addolorato
Antonio MirijelloAntonio Mirijello
Antonio Mirijello
LLLorenzo Leggio
Lorenzo Leggio
AFAnna Ferrulli
Anna Ferrulli
CDCristina D'ANgelo
Cristina D'ANgelo
GGGemelli OLT Group
Gemelli OLT Group

1 September 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
GAGiovanni Addolorato
Giovanni Addolorato
Antonio MirijelloAntonio Mirijello
Antonio Mirijello
PBPablo Barrio
Pablo Barrio
Antoni GualAntoni Gual
Antoni Gual

10 February 2015 in Drugs
Verified
Journal Article
Closed access
PDF file
Antonio MirijelloAntonio Mirijello
Antonio Mirijello
CDCristina D’aNgelo
Cristina D’aNgelo
AFAnna Ferrulli
Anna Ferrulli
GVGabriele Vassallo
Gabriele Vassallo
MAMariangela Antonelli
Mariangela Antonelli
GAGiovanni Addolorato
Giovanni Addolorato

17 March 2011 in Alcohol and Alcoholism
Verified
Journal Article
Open access
PDF file
GAGiovanni Addolorato
Giovanni Addolorato
LLLorenzo Leggio
Lorenzo Leggio
AFAnna Ferrulli
Anna Ferrulli
SCSilvia Cardone
Silvia Cardone
GBGiorgio Bedogni
Giorgio Bedogni
NNN. Nicotra
N. Nicotra
Aims: To explore the effect of baclofen in a dose of 20 mg three times per day, compared with the already studied dose of 10 mg three times per day, in the treatment of alcohol dependence. Methods: We present a secondary analysis of a 12-week double-blind, placebo-controlled, randomized clinical trial with two doses of baclofen, specifically 10 mg t.i.d. and 20 mg t.i.d. Out of 94 subjects consecutively screened, 42 were randomized into the study. Fourteen of the 42 patients were randomly allocated to placebo, 14 to the group treated with baclofen 10 mg t.i.d. (B10 mg) and 14 to the group treated with baclofen 20 mg t.i.d. (B20 mg). Results: Compared with patients allocated to placebo, patients allocated to the B10 mg group had a 53% reduction in the number of drinks per day (P < 0.0001) and patients allocated to the B20 mg group had a 68% reduction in the number of drinks per day (P < 0.0001), with respect to the number of drinks per day during the 28 days before randomization. The effect of baclofen 20 mg t.i.d. was greater than that of baclofen 10 mg t.i.d. (P = 0.0214, Wald test) showing a dose–effect relationship. Both doses of baclofen were well tolerated. Conclusion: This is provisional evidence of a dose–response effect for baclofen in the treatment of alcohol dependence.